Highlights Ardelyx, Inc.

Equities

ARDX

US0396971071

Real-time Estimate Cboe BZX Other stock markets 11:01:45 2024-06-20 EDT			5-day change	1st Jan Change
5.835 ^USD	-1.93%		-9.63%	-5.40%

05-24	Ardelyx Shares Fall; Chief Commercial Officer Resigns	MT
05-23	Ardelyx, Inc. Announces Rodriguez Would Resign as Chief Commercial Officer	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Ardelyx Shares Rise After Q1 Beat	05-03	MT
Top Premarket Gainers	05-03	MT
Earnings Flash (ARDX) ARDELYX Reports Q1 Revenue $46M, vs. Street Est of $36.4M	05-02	MT
Ardelyx, Inc. Provides IBSRELA Revenue Guidance for the Full Year 2024	05-02	CI
Ardelyx, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-02	CI
Ardelyx's Q4 Swings to Loss; Revenues Down; Shares Down After-Hours	02-23	MT
Ardelyx, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-22	CI
Ardelyx, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-22	CI
Earnings Flash (ARDX) ARDELYX Posts Q4 Revenue $34.4M, vs. Street Est of $34.2M	02-22	MT
ARDELYX INC: JEFFERIES RAISES TARGET PRICE TO $11 FROM $8…	01-09	RE
Ardelyx Provides Update On 2024 Strategic Priorities	01-08	RE
Ardelyx, Inc. Announces XPHOZAH(R) Now Available in the United States	11-06	CI
Ardelyx Shares Positive Data from Studies of Xphozah®? At Asn Kidney Week 2023	11-03	CI
Earnings Flash (ARDX) ARDELYX Reports Q3 Revenue $56.4M, vs. Street Est of $22.6M	23-10-31	MT
Ardelyx, Inc. Provides Earnings Guidance for the Full Year 2023	23-10-31	CI
Ardelyx, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-31	CI
Ardelyx, Inc. Shares Positive Data on Symptom Response During Treatment with IBSRELA®? for IBS-C and Hosts IBS-C Product Theater at ACG 2023	23-10-23	CI
US FDA approves Ardelyx's kidney disease-related drug	23-10-17	RE
Ardelyx, Inc. Announces FDA Approval of XPHOZAH, a First-In-Class Phosphate Absorption Inhibitor	23-10-17	CI
Ardelyx, Inc. Announces Publication of Positive Results from T3MPO-3 Long-Term Open-Label Safety Trial of Tenapanor for IBS-C in the Journal of Neurogastroenterology and Motility	23-09-28	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Ardelyx, Inc.

Equities

ARDX

US0396971071

Highlights

Filters